Leptin qA Ovine

Leptin Antagonist Quadruple Mutant Ovine Recombinant
Shipped with Ice Packs
In Stock

Description

Functional Properties

As a competitive leptin receptor (LEPR) antagonist, Leptin qA Ovine:

  • Blocks leptin-induced signaling by binding to LEPR without activating downstream JAK-STAT pathways .

  • Inhibits cellular proliferation in BAF/3 cells transfected with human LEPRb (IC50 ~6–8× higher than native leptin) .

  • Induces hyperphagia and weight gain in murine models during chronic infusion studies .

3.1. Metabolic Studies

  • Adrenal Steroidogenesis: In fetal sheep exposed to chronic hypoxia, Leptin qA Ovine infusion (1.5 mg·kg⁻¹·day⁻¹) reversed leptin-mediated suppression of cortisol by upregulating adrenal CYP11A1 and CYP17 expression .

  • Bone Remodeling: Central leptin administration in ewes reduced trabecular bone volume (BV/TV: 12.4% vs. 22.7% in controls) and osteoblast activity .

3.2. Pharmacokinetic Optimization

Pegylation (20 kDa PEG) enhances its hydrodynamic volume, prolonging half-life in vivo:

ParameterNon-PegylatedPegylated
Molecular Weight16 kDa35.6 kDa
In Vitro ActivityHighReduced (6–8×)
In Vivo EfficacyModerateEnhanced
StabilityWeeks at 4°CMonths at 4°C

Mechanism of Action

Leptin qA Ovine targets leptin’s receptor-binding domains:

  1. CRH2 Domain Binding: Retains affinity for LEPR’s cytokine receptor homology domain 2 (CRH2) .

  2. Activation Disruption: Mutations in the LDFI motif (residues 39–42) prevent conformational changes required for receptor activation .

  3. Cross-Reactivity: Effective in both ovine and human LEPR models .

Therapeutic Potential

While primarily a research tool, its applications include:

  • Obesity Research: Testing hypotheses about leptin resistance in diet-induced obesity models .

  • Neuroendocrine Studies: Investigating leptin’s role in growth hormone (GH) secretion under seasonal photoperiods .

Limitations and Considerations

  • Species Specificity: Higher efficacy in ovine models than rodents .

  • Dose Dependency: Pegylated forms require higher doses for equivalent in vitro effects .

Product Specs

Description
Leptin Antagonist Quadruple Mutant Ovine Recombinant is a single, non-glycosylated polypeptide chain containing 146 amino acids with an additional alanine at the N-terminus. It has a molecular mass of approximately 16 kDa. The Leptin protein was mutated, resulting in the L39A/D40A/F41A/I42A mutant. Leptin Antagonist Quadruple Mutant Ovine Recombinant was purified using proprietary chromatographic techniques.
Physical Appearance
White, lyophilized powder.
Formulation
The protein was lyophilized from a concentrated (1 mg/ml) solution containing 0.0045 mM sodium bicarbonate.
Solubility
It is recommended to reconstitute the lyophilized Leptin-Antagonist Quadruple Mutant Ovine Recombinant in sterile 0.4% sodium bicarbonate adjusted to a pH of 8-9, at a concentration not less than 100 µg/ml. This can then be further diluted to other aqueous solutions.
Stability
Lyophilized Leptin-Antagonist Quadruple Mutant Ovine Recombinant is stable at room temperature for several weeks, but should be stored desiccated below -18°C for long-term storage. Upon reconstitution at concentrations greater than 0.1 mg/ml and up to 2 mg/ml, and after filter sterilization, the Leptin mutant can be stored at 4°C or even room temperature for several weeks, making it suitable for long-term infusion studies using osmotic pumps. At lower concentrations, adding a carrier protein (0.1% HSA or BSA) is recommended. Avoid freeze-thaw cycles.
Purity
Greater than 98.0% as determined by: (a) Gel filtration analysis. (b) SDS-PAGE analysis.
Biological Activity
THE BioTek's leptin qA can inhibit the proliferation of BAF/3 cells stably transfected with the long form of the ovine leptin receptor, which is induced by leptin. It also inhibits various effects of leptin in several in vitro bioassays.
Protein Content
Protein quantitation was carried out using UV spectroscopy at 280 nm. An absorbance value of 0.21 was used as the extinction coefficient for a 0.1% (1 mg/ml) solution at a pH of 8.0. This value is calculated using the PC GENE computer analysis program for protein sequences (IntelliGenetics).
Source
Escherichia coli.
Amino Acid Sequence
The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Val-Pro-Ile-Arg.

Q&A

What is the molecular structure of recombinant ovine leptin?

Recombinant ovine leptin consists of a single polypeptide chain containing 146 amino acids with a molecular weight of approximately 16 kDa. This structure differs slightly from modified variants such as MTS-leptin, which has a higher molecular weight of approximately 17.5 kDa . Like other mammalian leptins, ovine leptin belongs to the growth hormone four-helical cytokine subfamily, characterized by four antiparallel α-helices connected by two long crossover links. The structural integrity of the protein depends on a crucial disulfide bridge formed by two cysteine residues that are essential for stability and biological activity .

How do ovine leptin receptors function in signaling pathways?

Ovine leptin receptors (ObRs) function similarly to those in other species, with multiple isoforms sharing the same extracellular domain structure. The receptors contain two cytokine receptor homology (CRH) domains separated by an immunoglobulin (Ig)-like domain, followed by two membrane-proximal fibronectin type III domains. The CRH2 domain is essential for high-affinity leptin binding, while the fibronectin domains, though lacking affinity for leptin, are crucial for receptor activation. The primary signaling pathway activated by leptin receptor binding is the JAK/STAT pathway, particularly through the ObRb isoform which contains the intracellular domain necessary for JAK2 association . Additionally, leptin activates the ERK1/2 MAPK pathway and can stimulate STAT5 both in vitro and in vivo, with STAT5 binding primarily to phosphorylated Tyr1077 of ObRb .

What methodological approaches should be used when comparing different recombinant leptin variants in sheep?

When comparing different recombinant leptin variants in sheep, researchers should implement a controlled experimental design that accounts for:

  • Photoperiodic conditions: Experimental protocols must standardize or explicitly control for photoperiod (long-day vs. short-day) as the effects of leptin variants show significant photoperiod-dependent differences .

  • Nutritional status control: Establish consistent feeding protocols with clearly defined fed and fasted states, as nutritional status significantly affects endogenous leptin concentrations and responses to exogenous leptin. Research demonstrates that leptin concentrations are higher in fasted ewes during long-day seasons .

  • Dosage standardization: When comparing variants like recombinant ovine leptin and MTS-leptin, dosages should be standardized based on biological activity rather than just molecular weight to account for potential differences in potency.

  • Measurement of multiple parameters: Assessment should include not only changes in leptin concentration but also downstream effects such as expression of leptin receptors (particularly LeptRa and LeptRb) and associated factors like VEGFA and VEGFR2 in relevant tissues .

  • Control groups: Include both untreated controls and comparative treatments with established leptin variants to enable meaningful comparisons.

How should researchers account for seasonal variations in ovine leptin studies?

Seasonal variations significantly impact leptin dynamics in sheep, requiring specific methodological considerations:

  • Explicit photoperiod documentation: All experiments should clearly document and control photoperiod conditions, as leptin concentrations in sheep can be 2-3 fold lower in short-day versus long-day seasons .

  • Season-specific baseline establishment: Before intervention studies, establish baseline leptin parameters specific to the season of experimentation, as reference values vary significantly.

  • Comparative seasonal designs: For comprehensive understanding, consider cross-seasonal experimental designs that test the same interventions across different photoperiods.

  • Controlled environmental conditions: Standardize temperature, light exposure (intensity and duration), and feeding schedules to minimize confounding variables beyond photoperiod.

  • Measurement of related seasonal factors: Include assessment of factors known to vary seasonally and interact with leptin, such as VEGFA expression in the choroid plexus, which plays a role in photoperiodic adaptation .

How does nutritional status affect leptin signaling in sheep?

Nutritional status exerts profound effects on leptin signaling in sheep through multiple mechanisms:

  • Endogenous leptin concentration changes: Fasting (72h) significantly alters circulating leptin levels, with the direction of change being photoperiod-dependent. Interestingly, leptin concentrations can be higher in fasted ewes during long-day seasons compared to short-day seasons .

  • Leptin receptor expression modulation: Nutritional status modifies the expression of leptin receptors, particularly affecting the ratio of long-form (LeptRb) to short-form (LeptRa) receptors in hypothalamic and peripheral tissues.

  • Blood-brain barrier transport mechanisms: Fasting affects components of the leptin transport system across the blood-brain barrier, including expression of VEGFA and VEGFR2 in the choroid plexus .

  • Central leptin sensitivity: The nutritional state alters central leptin sensitivity, with evidence suggesting that fasting can lead to adaptive responses that modify leptin's effects on orexigenic and anorexigenic pathways in the hypothalamus.

  • Interaction with other metabolic hormones: Nutritional status changes the hormonal milieu, affecting insulin, glucocorticoids, and other factors that interact with leptin signaling pathways .

What experimental approaches are effective for studying leptin resistance in sheep?

Effective experimental approaches for studying leptin resistance in sheep include:

  • Chronic leptin administration protocols: Administering sustained levels of recombinant ovine leptin to identify diminishing responses in food intake, body weight, and metabolic parameters over time.

  • Molecular marker assessment: Measuring expression of suppressor of cytokine signaling 3 (SOCS3), which is increased during leptin resistance and reduces leptin receptor signaling by inhibiting JAK2 activation .

  • Central vs. peripheral leptin sensitivity testing: Comparing responses to centrally (intracerebroventricular) vs. peripherally administered leptin to differentiate between transport-based and signaling-based resistance mechanisms.

  • Blood-brain barrier transport studies: Examining leptin transport across the blood-brain barrier by measuring cerebrospinal fluid:serum leptin ratios and assessing transport-related proteins like VEGFA in the choroid plexus .

  • Adipokine interaction models: Co-administration of leptin with other adipokines like resistin, which has been shown to create leptin central insensitivity during long-day photoperiods by increasing SOCS3 expression and decreasing LeptRb expression in the hypothalamus .

How can ovine leptin be utilized in embryonic development research?

Ovine leptin offers valuable research applications in embryonic development through several methodological approaches:

  • In vitro embryo culture supplementation: Adding recombinant leptin at optimized concentrations (research indicates 20 ng/mL may be optimal) to embryo culture media can improve blastocyst development rates .

  • Oxidative stress modulation: Leptin can be used experimentally to counteract oxidative stress in embryos, particularly those subjected to stressors like vitrification. Research demonstrates that leptin treatment significantly decreases pro-oxidant biomarkers (MDA, NO) while increasing antioxidant biomarkers (TAC, SOD, GPx) in both fresh and vitrified embryos .

  • Apoptosis pathway investigation: Leptin supplementation provides a model for studying anti-apoptotic mechanisms, as it has been shown to decrease apoptotic markers like BAX and TNFα while increasing protective factors like HSP60 .

  • Developmental competence assessment: Using leptin supplementation while measuring developmental biomarkers (SOX2, NANOG, OCT4) enables researchers to investigate factors affecting embryonic developmental potential .

  • Cryopreservation protocol optimization: Leptin can be incorporated into pre- and post-vitrification protocols to assess potential protective mechanisms against cryoinjury.

What mechanisms explain leptin's anti-inflammatory and neuroprotective effects in ovine models?

The anti-inflammatory and neuroprotective effects of leptin in ovine models operate through several mechanisms:

  • Modulation of inflammasome activation: Leptin can influence the NLRP3 inflammasome complex, which integrates stress-associated signals and regulates the production of pro-inflammatory cytokines like IL-1β that play key roles in anxiety and depression .

  • Cytokine regulation: Leptin affects the balance between pro- and anti-inflammatory cytokines in the central nervous system, potentially mitigating neuroinflammatory processes.

  • Oxidative stress reduction: Leptin exhibits antioxidant properties by increasing the activity of antioxidant enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GPx), while reducing malondialdehyde (MDA) and nitric oxide (NO) levels .

  • Anti-apoptotic signaling: Leptin activates anti-apoptotic pathways, decreasing the expression of pro-apoptotic factors like BAX and TNFα while increasing protective factors like heat shock proteins .

  • Neuronal cell survival promotion: By activating the JAK/STAT and ERK1/2 MAPK pathways in neurons, leptin promotes cell survival signals that can protect against various neuronal insults .

How should researchers address the confounding effects of body condition in leptin studies?

To address body condition confounding effects in ovine leptin studies:

  • Standardized body condition scoring: Implement consistent body condition scoring using the standard 1-5 scale for sheep before group assignments and throughout experimental periods.

  • Body composition analysis: When possible, utilize more precise methods like dual-energy X-ray absorptiometry (DEXA) or computed tomography to quantify fat deposits rather than relying solely on visual scoring.

  • Stratified experimental design: Group animals with similar body conditions together or employ a stratified design that accounts for body condition as a variable.

  • Statistical approaches: Use body condition as a covariate in statistical analyses to control for its effects on measured outcomes.

  • Longitudinal monitoring: Track changes in body condition throughout experiments to account for potential time-dependent effects.

What are the key considerations for measuring central versus peripheral leptin action in sheep?

Key considerations for differentiating central versus peripheral leptin action in sheep include:

  • Administration route comparison: Design experiments that compare responses to leptin administered via different routes: intracerebroventricular (ICV) for central effects versus intravenous or subcutaneous for peripheral effects.

  • Blood-brain barrier transport assessment: Measure leptin transport across the blood-brain barrier by examining the expression of transport-related proteins in the choroid plexus, such as VEGFA and VEGFR2, and by comparing CSF:serum leptin ratios .

  • Central-specific markers: Assess activation of hypothalamic nuclei through markers like c-Fos expression or phosphorylation of STAT3 in specific nuclei like the arcuate nucleus.

  • Leptin receptor isoform differentiation: Employ techniques to distinguish between activation of different leptin receptor isoforms, particularly the full-length ObRb (predominantly central) versus shorter isoforms (often peripheral).

  • Tissue-specific knockout models: When possible, utilize tissue-specific leptin receptor knockout or knockdown approaches to isolate central versus peripheral actions.

How might ovine leptin studies contribute to understanding photoperiodic regulation of metabolism?

Ovine leptin research offers unique opportunities for understanding photoperiodic regulation of metabolism:

  • Seasonal rhythmicity models: Sheep provide an excellent model for studying natural seasonal rhythms in leptin production and sensitivity, as they show marked 2-3 fold differences in leptin concentrations between long-day and short-day photoperiods .

  • Hypothalamic plasticity investigation: Research can focus on how photoperiod modulates leptin's effects on hypothalamic plasticity, particularly in the arcuate nucleus where leptin influences orexigenic NPY/AgRP and anorexigenic POMC neurons .

  • Blood-brain barrier seasonal adaptations: Studies can explore how photoperiod affects the VEGF system in the choroid plexus, which influences barrier properties and leptin transport to the central nervous system .

  • Leptin resistance mechanisms: Investigating how photoperiod influences the development of leptin resistance can provide insights into seasonal adaptive mechanisms involving SOCS3 expression and leptin receptor downregulation .

  • Integration with other seasonal hormones: Research can examine interactions between leptin and other photoperiod-sensitive hormones like melatonin and thyroid hormones to understand complex seasonal metabolic regulation.

What emerging technologies might enhance precision in ovine leptin research?

Emerging technologies that could enhance precision in ovine leptin research include:

  • CRISPR-Cas9 gene editing: Developing sheep models with specific modifications to leptin, leptin receptor genes, or related signaling components to precisely study functional aspects.

  • Single-cell transcriptomics: Applying single-cell RNA sequencing to analyze cell-specific responses to leptin in hypothalamic and peripheral tissues with unprecedented resolution.

  • In vivo imaging techniques: Adapting methods like positron emission tomography (PET) with leptin-specific tracers to visualize leptin distribution and binding in live animals.

  • Optogenetics and chemogenetics: Implementing these techniques to selectively activate or inhibit leptin-responsive neurons to understand circuit-level effects of leptin signaling.

  • Biosensor development: Creating implantable biosensors that can continuously monitor leptin levels and downstream signaling events in real-time under natural conditions.

Product Science Overview

Introduction to Leptin

Leptin is a protein hormone predominantly produced by adipocytes (fat cells) and plays a crucial role in regulating energy balance by inhibiting hunger . It is often referred to as the “satiety hormone” or “starvation hormone” because it helps to regulate appetite and energy expenditure . Leptin levels are directly proportional to the amount of body fat, and it signals the brain about the energy status of the body .

Leptin Antagonists

Leptin antagonists are modified forms of leptin that inhibit its action. These antagonists are valuable in research and potential therapeutic applications, particularly in conditions where leptin’s effects need to be blocked, such as certain autoimmune diseases, cancer, and obesity . Leptin antagonists work by binding to leptin receptors without activating them, thereby preventing the natural leptin from exerting its effects .

Quadruple Mutant Leptin

The term “quadruple mutant” refers to a leptin molecule that has undergone four specific mutations. In the case of the Leptin Antagonist Quadruple Mutant, the mutations are L39A, D40A, F41A, and I42A . These mutations are designed to enhance the antagonist properties of leptin, making it more effective in blocking leptin receptors .

Ovine Recombinant Leptin

“Ovine” refers to sheep, and “recombinant” indicates that the protein is produced using recombinant DNA technology. Recombinant proteins are generated by inserting the gene encoding the protein into a host organism, such as bacteria or yeast, which then produces the protein . Ovine recombinant leptin is leptin derived from sheep and produced using this technology .

Leptin Antagonist Quadruple Mutant Ovine Recombinant

The Leptin Antagonist Quadruple Mutant Ovine Recombinant is a specific form of leptin antagonist that has been engineered with four mutations and produced using recombinant DNA technology in sheep . This protein is a single non-glycosylated polypeptide chain containing 146 amino acids, with an additional alanine at the N-terminus, and has a molecular mass of approximately 16 kDa .

Applications and Significance

The Leptin Antagonist Quadruple Mutant Ovine Recombinant is significant in both research and potential therapeutic applications. It is used to study the role of leptin in various physiological processes and diseases. By blocking leptin’s action, researchers can better understand its functions and develop new treatments for conditions such as obesity, autoimmune diseases, and cancer .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.